Follicum AB attends and sponsors a conference in Basel

October 9, 2017

Follicum AB attends and sponsors a conference in Basel

Follicum AB (“Follicum” or “the company”) announced today that the company will attend a conference in Basel (www.basle-manchester-forum.science) and will also sponsor the conference with a small amount of money. Since the German research group who generated important parts of Follicum’s research data on human skin and human hair follicles will attend the conference, this conference is considered to be of great value to Follicum, and will provide opportunities to discuss our findings. The conference takes place in Basel, Switzerland, 12-13 October 2017.

The conference organizers have created a unique international forum for basic and applied research for hair and hair follicles, skin repair and regenerative research through this conference. The conference is designed to gather a carefully selected group of active researchers in plastic surgery, dermatology and basic developmental biology and is open to invited researchers only, with the aim of creating a forum for networking and for the opportunity to establish contacts between industry and academia. In addition, the conference is intended to create new cross-border co-operation across the various disciplines. For Follicum, this is a unique opportunity to create contacts and generate interest in the company’s projects.

CEO Jan Alenfall comments
“We are very pleased that Follicum and its research are noted in this way and are very positive to this unique conference. This gives us new opportunities to expose the company and our projects.

For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: 046 – 19 21 97
E-mail: info@follicum.com

About Follicum AB
Follicum was founded in 2011 by two researchers in Lund, Anna Hultgårdh and Pontus Dunér, based on research around a human protein, osteopontin. Among other things, this protein is considered to be involved in the growth of bone tissue. Follicum has isolated a part of this protein and partially modified its amino acid sequence, which generated Follicum’s drug candidate FOL-005. In early studies, FOL-005 showed an ability to both stimulate and inhibit hair growth. During 2016/2017, the company conducted its first clinical phase I/IIa study. Follicum is based in Lund and was listed on AktieTorget in 2014. www.follicum.se/en

Open as pdf